GlassScriptPhysician profile
Anne E Constantino
NPI 1134197221
$1,506.74
in general payments reported to CMS, 2019-2025
26 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $214 · 2021: $61.93 · 2022: $231 · 2023: $59.74 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.85 | 2019-2023 | Qulipta, Botox |
| Allergan, INC. | $136.93 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $127.37 | 2019-2020 | |
| Cala Health, INC. | $111.58 | 2025 | Cala Kiq |
| Ucb, INC. | $80.80 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $66.02 | 2019 | |
| Emd Serono, INC. | $61.06 | 2019-2020 | |
| Lundbeck LLC | $57.01 | 2019-2020 | |
| Lilly USA, LLC | $56.18 | 2019-2020 | |
| Mdd US Operations, LLC | $48.53 | 2019 | |
| Acadia Pharmaceuticals INC | $47.94 | 2019 | |
| Acorda Therapeutics, INC | $33.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $31.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.48 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $31.03 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $30.08 | 2019 | |
| Vertical Pharmaceuticals, LLC | $29.97 | 2019 | |
| Merz North America, INC. | $29.94 | 2019 | |
| Zyla Life Sciences, INC. | $29.07 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $27.10 | 2019-2020 | |
| Grifols USA, LLC | $23.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.09 | 2021 | |
| Boston Scientific Corporation | $17.64 | 2019 | |
| Kyowa Kirin, INC. | $17.56 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.88 | 2022 | |
| Horizon Therapeutics Plc | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Constantino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.